ArticleThrombosis and haemostasis2011
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
Article in Thrombosis and haemostasis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 99 citations in OpenAlex.
- Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals.Thrombosis and haemostasis · 2026Review
- Associations between rivaroxaban dose, gut microbiota, and coagulation parameters in a rat model.Thrombosis journal · 2025Article
- The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence.Journal of thrombosis and thrombolysis · 2023Review
- Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.Journal of atherosclerosis and thrombosis · 2022Article
- The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.Research and practice in thrombosis and haemostasis · 2022Article
- Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.International journal of molecular sciences · 2022Review
- Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.Blood transfusion = Trasfusione del sangue · 2018Article
- [Management of hemorrhage in patients treated with direct oral anticoagulants].Der Anaesthesist · 2017Review
- [Monitoring of NOAC].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2017Article
- In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.Blood transfusion = Trasfusione del sangue · 2016Article
- Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2015Observational
- Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.BioMed research international · 2015Review
- Measurement of rivaroxaban and apixaban in serum samples of patients.European journal of clinical investigation · 2014Article
- Safety of new oral anticoagulant drugs: a perspective.Therapeutic advances in drug safety · 2014Review
- Rivaroxaban and hemostasis in emergency care.Emergency medicine international · 2014Review
- New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness.Drug design, development and therapy · 2014Review
- Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.Therapeutics and clinical risk management · 2014Review
- Main considerable factors for correct laboratory test interpretation under DOA treatment.Thrombosis journal · 2013Article
- Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.Journal of thrombosis and thrombolysis · 2013Review
- Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It was the objective of this study to quantify the effects of rivaroxaban administration on global coagulation parameters associated with routine clinical procedures, we collected plasma samples from patients undergoing major orthopaedic surgery receiving rivaroxaban at various time points after drug administration. Forty-seven patients received rivaroxaban (10 mg daily) for venous thromboembolism prophylaxis. Blood samples were collected at four different time points: A) before surgery; B) before drug administration at day 4-5 after surgery (steady state of rivaroxaban); C) 2 hours (h) after drug administration and D) 12 h after drug administration. The prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), antithrombin (AT) level, fibrinogen level by Clauss method (FibC), and derived fibrinogen (dFIB) level were assessed with various reagents. At 2 h after rivaroxaban administration, the PT and aPTT clotting times were significantly prolonged to different extents up to 1.4 fold, whereas 12 h after drug administration, no significant effect was observed. Rivaroxaban administration had no influence on the TT or the FibC concentration. The dFIB assay was differentially affected by rivaroxaban when different reagents were tested. The AT assay dependent on thrombin activity was not influenced by rivaroxaban, whereas the AT levels dependent on factor Xa activity were significantly increased by rivaroxaban. Clinicians should be aware of the time-dependent influence of rivaroxaban on factor Xa-dependent routine coagulation assays. Therefore, routine coagulation parameters should be assessed directly before drug administration to keep the interaction of rivaroxaban low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.